NO982332L - Salter av kinolin-derivater som NK3 antagonister - Google Patents

Salter av kinolin-derivater som NK3 antagonister

Info

Publication number
NO982332L
NO982332L NO982332A NO982332A NO982332L NO 982332 L NO982332 L NO 982332L NO 982332 A NO982332 A NO 982332A NO 982332 A NO982332 A NO 982332A NO 982332 L NO982332 L NO 982332L
Authority
NO
Norway
Prior art keywords
antagonists
salts
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
NO982332A
Other languages
English (en)
Other versions
NO982332D0 (no
NO310866B1 (no
Inventor
Giuseppe Arnaldo Mari Giardina
Carlo Farina
Mario Grugni
Luca Francesco Raveglia
Original Assignee
Smithkline Beecham Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa
Publication of NO982332D0 publication Critical patent/NO982332D0/no
Publication of NO982332L publication Critical patent/NO982332L/no
Publication of NO310866B1 publication Critical patent/NO310866B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19982332A 1995-11-24 1998-05-22 Kinolin-salthydrat som NK3-antagonist NO310866B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9524137.8A GB9524137D0 (en) 1995-11-24 1995-11-24 Novel compounds
PCT/EP1996/005210 WO1997019928A1 (en) 1995-11-24 1996-11-22 Salts of quinoline derivatives as nk3 antagonists

Publications (3)

Publication Number Publication Date
NO982332D0 NO982332D0 (no) 1998-05-22
NO982332L true NO982332L (no) 1998-05-22
NO310866B1 NO310866B1 (no) 2001-09-10

Family

ID=10784449

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982332A NO310866B1 (no) 1995-11-24 1998-05-22 Kinolin-salthydrat som NK3-antagonist

Country Status (23)

Country Link
US (3) US6355654B1 (no)
EP (1) EP0876348B1 (no)
JP (1) JP4377454B2 (no)
KR (1) KR19990071599A (no)
CN (1) CN1207728A (no)
AR (1) AR004970A1 (no)
AT (1) ATE233243T1 (no)
AU (1) AU722451B2 (no)
BR (1) BR9611729A (no)
CA (1) CA2238312A1 (no)
CZ (1) CZ158198A3 (no)
DE (1) DE69626416T2 (no)
ES (1) ES2192621T3 (no)
GB (1) GB9524137D0 (no)
HU (1) HUP9903584A3 (no)
IL (1) IL124352A0 (no)
MX (1) MX9804106A (no)
NO (1) NO310866B1 (no)
NZ (1) NZ323389A (no)
PL (1) PL326927A1 (no)
TR (1) TR199800925T2 (no)
WO (1) WO1997019928A1 (no)
ZA (1) ZA969812B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
US6413982B1 (en) 1999-03-29 2002-07-02 Neurogen Corporation 4-substituted quinoline derivatives
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
AU2006253054A1 (en) * 2005-06-03 2006-12-07 Astrazeneca Ab Quinoline derivatives as NK3 anatgonists
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
EP1919871A4 (en) * 2005-08-02 2010-08-18 Glaxosmithkline Llc PROCESS FOR SYNTHESIS OF CHINOLINE DERIVATIVES
JP2009504642A (ja) * 2005-08-11 2009-02-05 アストラゼネカ・アクチエボラーグ Ｎｋ−３受容体の調節剤としてのオキソピリジルキノリンアミド
WO2007035156A1 (en) * 2005-09-21 2007-03-29 Astrazeneca Ab N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands
AR057130A1 (es) * 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
EP1981882A4 (en) * 2006-01-27 2009-11-18 Astrazeneca Ab QUINOLINES SUBSTITUTED BY AN AMIDE
FR2979173B1 (fr) * 2011-08-19 2013-08-16 St Microelectronics Grenoble 2 Commutateur analogique basse tension
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
AU2014255512A1 (en) 2013-04-19 2015-11-12 Astrazeneca Ab A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226535B1 (en) 1994-05-27 2009-03-30 Glaxosmithkline Spa Quinoline derivatives as tachykinin nk3 receptor antagonists, pharmaceutical compositions containing them, and their use
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
AU722451B2 (en) 2000-08-03
CZ158198A3 (cs) 1998-10-14
US20020077335A1 (en) 2002-06-20
TR199800925T2 (xx) 2001-05-21
WO1997019928A1 (en) 1997-06-05
MX9804106A (es) 1998-09-30
GB9524137D0 (en) 1996-01-24
HUP9903584A3 (en) 2001-10-29
NO982332D0 (no) 1998-05-22
IL124352A0 (en) 1998-12-06
JP4377454B2 (ja) 2009-12-02
PL326927A1 (en) 1998-11-09
CN1207728A (zh) 1999-02-10
EP0876348B1 (en) 2003-02-26
KR19990071599A (ko) 1999-09-27
BR9611729A (pt) 1999-04-06
CA2238312A1 (en) 1997-06-05
JP2000500770A (ja) 2000-01-25
AR004970A1 (es) 1999-04-07
ZA969812B (en) 1998-05-22
US6355654B1 (en) 2002-03-12
DE69626416T2 (de) 2003-12-24
US6432977B1 (en) 2002-08-13
DE69626416D1 (de) 2003-04-03
ES2192621T3 (es) 2003-10-16
NO310866B1 (no) 2001-09-10
HUP9903584A2 (hu) 2000-02-28
US20020156097A1 (en) 2002-10-24
AU1031997A (en) 1997-06-19
EP0876348A1 (en) 1998-11-11
NZ323389A (en) 2000-02-28
ATE233243T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
NO965036D0 (no) Kinolinderivater som techykinin NK3 reseptor-antagonister
NO982332D0 (no) Salter av kinolin-derivater som NK3 antagonister
DE69634416D1 (de) Chinolin-derivate
NO981141D0 (no) Kinolin-2(1H)-on derivater som serotoninantagonister
DK0839136T3 (da) Benzo[g]quinolinderivater
DK0922034T3 (da) Tetrahydroquinolinderivater som EAA-antagonister
NO974043L (no) Indolderivater som EAA-antagonister
DK0854867T3 (da) Tetrahydroquinoliner som NMDA-antagonister
NO982843L (no) 2,7-Substituerte oktahydro-pyrrol£1,2-a|pyrazin-derivater
NO20001387D0 (no) Fremgangsmåte for syntese av kinolinderivater
NO961333D0 (no) Nye pyrazolderivater som angiotensin-II-antagonister
NO20003960D0 (no) Salter av paroksetin
NO20006547D0 (no) Salter av paroxetine
NO950684L (no) Nye imidazopyridinderivater som angiotensin II-antagonister
DK0940391T3 (da) Quinolinderivater som tachykinin-NK3-receptor-antagonister
NO940131D0 (no) Salter av 4-pyrimidinon-derivater for framasoeytisk anvendelse
FI970143A0 (fi) Kinoliinijohdannaiset leukotrieeniantagonisteina
NO920022L (no) Umettede hydroksyalkylkinolinsyrer som leukotrienantagonister

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN MAY 2003